Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28729351 | 1.00 | KCNH2 (0.41) | KCNH2KCNA5HTTKMT2AMEN1 | |
| SCHEMBL23509964 | 0.98 | KCNH2 (0.39) | KCNH2KCNA5HTTKMT2AMEN1 | |
| SCHEMBL29257758 | 0.81 | — | — | |
| SCHEMBL19865652 | 0.81 | KCNH2 (0.43) | KCNH2KCNA5HTTKMT2AMEN1 | |
| SCHEMBL9738468 | 0.81 | KCNH2 (0.43) | KCNH2KCNA5HTTKMT2AMEN1 | |
| SCHEMBL23381218 | 0.81 | KCNH2 (0.43) | KCNH2KCNA5HTTKMT2AMEN1 | |
| SCHEMBL19505906 | 0.81 | KCNH2 (0.43) | KCNH2KCNA5HTTKMT2AMEN1 | |
| SCHEMBL18403079 | 0.81 | KCNH2 (0.43) | KCNH2KCNA5HTTKMT2AMEN1 | |
| SCHEMBL9740019 | 0.81 | KCNH2 (0.43) | KCNH2KCNA5HTTKMT2AMEN1 | |
| SCHEMBL27272370 | 0.81 | KCNH2 (0.43) | KCNH2KCNA5HTTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215888-A1 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2009-08-27 | — | — | US | claimed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | claimed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2007098591-A2 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2007-09-07 | — | — | WO | claimed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| CN-110636833-B | Topical treatment of cutaneous malignant tumors using taxane nanoparticles | DFB索里亚有限责任公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-112243372-A | Methods and cancer vaccines for isolating tumor-specific immune cells from a subject for adoptive cell therapy | 克里蒂泰克公司 | 2021-01-19 | — | — | CN | disclosed |
| CN-112165949-A | Topical therapy using taxane nanoparticles for the treatment of Cervical Intraepithelial Neoplasia (CIN) and cervical cancer | DFB索里亚有限责任公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-110636833-A | Topical therapy using taxane nanoparticles for the treatment of skin malignancies | DFB索里亚有限责任公司 | 2019-12-31 | — | — | CN | disclosed |
| EP-2411032-B1 | PLANT EXTRACTS FOR THE TREATMENT OF SKIN DISEASES | EVORIA GMBH (DE) | 2014-07-09 | — | — | EP | disclosed |
| US-20120269914-A1 | PLANT EXTRACTS FOR TREATING SKIN DISEASES | EVORIA GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-8277762-B2 | Apparatus and methods for evaluating the barrier properties of a membrane | TIOGA RESEARCH, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090215888-A1 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2009-08-27 | — | — | US | disclosed |
| US-20090105260-A1 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2009-04-23 | — | — | US | disclosed |
| US-20080319092-A1 | Transdermal Drug Delivery Formulation | NUVO RESEARCH INC. (CA) | 2008-12-25 | — | — | US | disclosed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | disclosed |
| WO-2007098591-A2 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2007-09-07 | — | — | WO | disclosed |
| US-20070183936-A1 | Apparatus and methods for evaluating the barrier properties of a membrane | NUVO RESEARCH US, INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105260-A1 | Molecules to Enhance Percutaneous Delivery and Methods for Discovery Therefor | NOTUM, TRPV1, TRPV4 | KCNH2 2038/4885KCNA5 2267/4885HTT 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.